Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients with B-CLL

Patient no.	Sex	Age, y	Rai stage	Cytogenetics	Mutation status	Percent viability after 24-h honokiol treatment
1	Male	78	III	—	—	11
2	Male	36	I	Trisomy 12; normal p53; IgH rearranged	UM	59.2
3	Female	52	I	—	M	5.5
4	Male	50	II	del 13q	M	26.9
5	Male	39	IV	del 13q; del 17p	UM	38
6	Male	57	IV	del 9q	UM	24.9
7	Female	65	III	Trisomy 12	—	22.6
8	Female	52	I	del 13q	M	11.1
9	Male	51	I	del 13q	M	8.3
10	Male	57	I	Normal	UM	60
11	Female	52	III	Normal	—	30
12	Female	44	II	Normal	M	49
13	Male	51	II	Normal	M	17.2
14	Female	64	I	Trisomy 12	UM	35.2
15	Female	49	II	Normal	M	40
16	Male	61	III	del 12 centromere; del 13q	M	44.6
17	Female	50	I	Normal	UM	31.8
18	Male	50	I	Normal	UM	11.6
19	Female	60	III	—	—	9.1

Patient no.	Sex	Age, y	Rai stage	Cytogenetics	Mutation status	Percent viability after 24-h honokiol treatment
1	Male	78	III	—	—	11
2	Male	36	I	Trisomy 12; normal p53; IgH rearranged	UM	59.2
3	Female	52	I	—	M	5.5
4	Male	50	II	del 13q	M	26.9
5	Male	39	IV	del 13q; del 17p	UM	38
6	Male	57	IV	del 9q	UM	24.9
7	Female	65	III	Trisomy 12	—	22.6
8	Female	52	I	del 13q	M	11.1
9	Male	51	I	del 13q	M	8.3
10	Male	57	I	Normal	UM	60
11	Female	52	III	Normal	—	30
12	Female	44	II	Normal	M	49
13	Male	51	II	Normal	M	17.2
14	Female	64	I	Trisomy 12	UM	35.2
15	Female	49	II	Normal	M	40
16	Male	61	III	del 12 centromere; del 13q	M	44.6
17	Female	50	I	Normal	UM	31.8
18	Male	50	I	Normal	UM	11.6
19	Female	60	III	—	—	9.1

All patients were untreated at the time of this study. Mutation status refers to immunoglobulin VH (IgVH) gene mutation status. B-CLL cells were treated in vitro with 40 μM honokiol for 24 hours, and viability was determined by measuring the level of ATP as an indicator of metabolic activity using a luminescence-based assay.

UM indicates unmutated; M, mutated; del, deletion; and -, information unavailable.

View Large

This Feature Is Available To Subscribers Only